| 16.505 -0.005 (-0.03%) | 12-08 13:13 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 32.42 | 1-year : | 41.27 |
| Resists | First : | 27.76 | Second : | 35.34 |
| Pivot price | 26.36  |
|||
| Supports | First : | 15.51 | Second : | 12.9 |
| MAs | MA(5) : | 16.48 |
MA(20) : | 26.85 |
| MA(100) : | 25.28 |
MA(250) : | 0 | |
| MACD | MACD : | -2.5 |
Signal : | -0.6 |
| %K %D | K(14,3) : | 4.9 |
D(3) : | 5 |
| RSI | RSI(14): 30.1 |
|||
| 52-week | High : | 61.59 | Low : | 15.51 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ JANX ] has closed above bottom band by 16.4%. Bollinger Bands are 443.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 8 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 16.55 - 16.67 | 16.67 - 16.76 |
| Low: | 15.78 - 15.91 | 15.91 - 16 |
| Close: | 16.35 - 16.54 | 16.54 - 16.69 |
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.
Mon, 08 Dec 2025
Reassessing Janux Therapeutics (JANX) Valuation After Mixed Market Reaction to New JANX007 Phase 1 Data - simplywall.st
Sat, 06 Dec 2025
Do JANX007’s Interim Results Put Janux Therapeutics’ (JANX) TRACTr Platform Competitiveness to the Test? - Yahoo Finance
Wed, 03 Dec 2025
Janux Therapeutics' (JANX) Outperform Rating Reaffirmed at Wedbush - MarketBeat
Wed, 03 Dec 2025
Janux Therapeutics: Downgrading To 'Hold' Rating After Latest Updated Phase 1 JANX007 mCRPC Data - Seeking Alpha
Tue, 02 Dec 2025
Stifel Maintains Janux Therapeutics (JANX) Buy Recommendation - Nasdaq
Tue, 02 Dec 2025
Janux Therapeutics Craters 53% On Prostate Cancer Update; Is It An 'Overreaction'? - Investor's Business Daily
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 60 (M) |
| Held by Insiders | 4.502e+007 (%) |
| Held by Institutions | 6.5 (%) |
| Shares Short | 8,560 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.4222e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -352.6 % |
| Return on Assets (ttm) | -10.5 % |
| Return on Equity (ttm) | -12.5 % |
| Qtrly Rev. Growth | 2 % |
| Gross Profit (p.s.) | 63.08 |
| Sales Per Share | 3.5461e+006 |
| EBITDA (p.s.) | -2.34965e+007 |
| Qtrly Earnings Growth | -1.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -70 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 2.87 |
| Dividend | 0 |
| Forward Dividend | 7.13e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|